PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “PLASMACYTOMA”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 937 records · Page 52Linked to original sources
PubMed1993

Solitary plasmacytoma of the mandible. Case report and review of the literature.

A case of solitary plasmacytoma of the mandible is presented. Review of the literature disclosed the following characteristics regarding the clinical course and prognosis. The patients ages ranged from 34 to 76 years, with a mean of 53 years; there was a marked preponderance of males. The site of predilection was the posterior portion of the mandible. The common symptom was a non-painful swelling of the mandible of long duration, and radiological features were non-specific. Monoclonal immunoglobulin was initially detected in 42% of the evaluated patients. The majority of patients were treated with radiation therapy with a mean dose of 48Gy with or without surgery. The period of follow-up ranged from 4 months to 12 years, and 17% of the patients progressed to multiple myeloma within 1 year.

Female↗
PubMed2003

Diffuse cutaneous plasmacytomas demonstrated on gallium-67 imaging.

Gallium-67 scanning is a useful tool to search for infectious foci and malignant tumors. Multiple myeloma is one clinical indication for gallium-67 tumor survey. Here, we report a rare case of diffuse multiple cutaneous plasmacytomas from recurrent multiple myeloma, demonstrated by whole-body gallium-67 scan.

Female↗
PubMed1977

Extramedullary plasmacytoma of the head and neck, parotid and submandibular salivary glands.

Twenty-two cases of extramedullary plasmacytomas (EMP) were diagnosed in the Birmingham region during 1962-1973. Five cases of EMP of the head and neck are discussed, including cases involving the parotid and submandibular salivary glands. Comparative data on incidence, age, sex, and survival is presented. A multidisciplinary approach is important for diagnosis, treatment and follow-up. It is mandatory to carry out investigations to exclude multiple myeloma. Radiotherapy is the treatment of choice; clinical, radiological and pathological evidence are cited. However, a residuum may be left after an initial response to radiotherapy which may require surgical removal. Chemotherapy has a place in multiple site lesions. A proportion of cases proceed to multiple myeloma after a variable period of time and thus follow-up should be life-long.

Adolescent↗
PubMed1985

Plasmacytoma of the nasopharynx (a case report with a follow-up of twelve years).

A case of plasmacytoma of the nasopharynx with a 12-year follow-up is reported. The difficulty in clinical and histological diagnosis is stressed. Despite the development of multiple metastatic lesions, repeated investigations for multiple myeloma were consistently negative. The patient was treated with a combination of radiotherapy, surgery and chemotherapy at different stages of the disease.

Follow-Up Studies↗
PubMed1991

Extramedullary nasal plasmacytoma.

The literature on this rare tumour has been reviewed and three cases of nasal plasmacytoma are described. Immunohistochemistry demonstrated cytoplasmic IgA and Kappa determinants in all cases. Two patients are disease-free at the present time, the third developed an IgG-k multiple myeloma, previously not described in the literature.

Aged↗
PubMed1991

Primary extramedullary plasmacytoma of the salivary glands.

Primary extramedullary plasmacytomas (PEMP) are uncommon plasma cell neoplasms that generally occur in the submucosal tissue of the upper airway. Salivary gland PEMP is an extremely rare condition. This report describes a unique case of PEMP in the parotid gland associated with pulmonary amyloidosis. A review of all salivary gland PEMP's suggests that they behave similarly to PEMP's in other locations. The treatment of choice for localized disease is radiotherapy which should include regional lymphatics. Local control can be achieved in the majority of cases. The minority of patients develop systemic metastases and die from their disease. Chemotherapy can control disseminated disease and may induce remission.

Aged↗
PubMed1994

Primary extramedullary plasmacytoma in the middle ear: differential diagnosis and management.

Primary extramedullary plasmacytoma (PEP) is an uncommon neoplasm of plasma cell origin which afflicts the head and neck mainly. In this study we report a rare case of a 34-year-old man who presented with left ear tinnitus, hearing loss, blocked feeling and headache. Exploratory tympanotomy revealed a mass extending into the attic and the mastoid antrum. Following canal wall-up mastoidectomy, the tumour was carefully removed. Histological examination (including immunoperoxidase staining) and thorough clinical, laboratory and radiological evaluation revealed an exclusively cytoplasmic monoclonal IgG immunoglobulin PEP. The combination of surgery (including a second-look procedure) and radiotherapy used in this case may be an over-treatment. However, the patient is still disease-free seven years after his first admission to hospital.

Adult↗
PubMed1996

Mechanism of apoptosis suppression by phorbol ester in IL-6-starved murine plasmacytomas: role of PKC modulation and cell cycle.

We show here that the mode of cell death in IL-6-starved T1165 and T1198 plasmacytoma cell lines is apoptosis, and that it can be suppressed by phorbol ester (PMA) treatment in a protein kinase C (PKC)-mediated process that involves alpha and/or delta isozymes. PMA-induced PKC activation, but not the depletion that follows it, participates in the suppression of apoptosis. Extended PKC activation is necessary but not sufficient for the apoptosis suppression. In addition, the cells must be in a "competent" state, which appears not to be determined by PKC. We observed two points of "competence" during the time between withdrawal of IL-6 and the start of massive cell death: one, immediately after withdrawal, and another, just before onset of apoptosis, at the time corresponding to maximal accumulation of cells in a G0/G1 block imposed by IL-6 withdrawal. Treatment with PMA and other PKC activators resulted in a shift of the cell population to S phase, lifting the G0/G1 block. We propose a model in which cells are rescued in a certain stage of the G1 phase of cell cycle. Death suppression occurs when a transient PMA-induced PKC activation occurs when a significant number of cells are in this part of G1, allowing them to pass the restriction point safely without initiating the cell death program.

Alkaloids↗
PubMed1989

Analogues of cisplatin derived from diaminodideoxytetritols. Synthesis and activity against the ADJ/PC6 plasmacytoma in mice.

Four new analogues of the anticancer drug cisplatin have been prepared that contain a diaminodideoxytetritol derivative as the amine ligand moiety, and their activities have been measured against the ADJ/PC6 plasmacytoma in mice. Two of these compounds, the enantiomers of cis-dichloro(1,4-diamino-1,4-dideoxy-2,3-O-isopropylidenethreitol) -platinum(II) , show a higher TI value than cisplatin when administered by intraperitoneal injection and, importantly, show significant antitumour activity when administered orally.

Administration, Oral↗
PubMed2002

The impact of p53 loss on murine plasmacytoma development.

Mouse plasmacytomas (PCTs) are characterized by c-myc-activating translocations that juxtapose c-myc on chromosome 15 onto one of the immunoglobulin loci (IgH on chromosome 12, IgK on chromosome 6, or IgA on chromosome 16). To assess the impact of p53 loss on PCT genesis, we induced PCTs in p53-deficient BALB/cRb6.15 mouse strains. We show that p53 loss accelerates tumor development and causes a shift in the typical translocation patterns. PCTs that carry variant T(6;15) translocations become as frequent as those with typical T(12;15) translocations (41.66%). In addition, in the absence of p53, the number of translocation-negative PCTs increases from less than 1% to 16.66%. It is noteworthy that neither the shortened latency periods nor the shift in translocation patterns had an impact on the incidence of PCT development. The 42.2% incidence in N3p53-/- mice is similar to the percentages recorded in groups of conventional BALB/cAn mice. The possible mechanisms underlying the accelerated tumorigenesis and the shift in translocation patterns are discussed.

Animals↗
PubMed1999

[Primary extramedullary plasmacytoma of the duodenum].

INTRODUCTION: Primary extramedullary plasmacytoma (EMP) is a solitary tumor that arises outside the bone marrow in patients without clinical evidence of coexisting multiple myeloma. EMP represents only 4% of all patients with plasma cell malignancies. The tumor generally occurs in the submucosal tissue of the upper airway or oral cavity. 10% of all EMP occur in the gastrointestinal tract. Only 8 cases of EMP in the duodenum have been reported in literature. METHOD: The authors present a case of EMP in the duodenum in a 53 year old men. The tumor was initially misdiagnosed as desmoid tumor. With a combined treatment of surgery and chemotherapy complete remission for 2 years was achieved, followed by a dissemination of the tumor in the testis, mandibular bone and ribs. CONCLUSION: EMP is a rare differential diagnosis of an intraabdominal tumor. Diagnosis is difficult, and in most reported cases it is confirmed only postoperatively after immunohistochemical staining. Combined treatment of surgery and chemotherapy seem to offer the best potential for cure.

Diagnosis, Differential↗
PubMed2002

Primary marginal zone B-cell lymphoma of the lymph node resembling plasmacytoma arising from a plasma cell variant of Castleman's disease. A clinicopathological and immunohistochemical study of seven patients.

Nodal marginal zone B-cell lymphomas (NMZBL) occasionally represent prominent plasma cell differentiation. Recently, we presented a patient with NMZBL who exhibited histological features that resembled plasmacytoma arising from a localized plasma cell variant of Castleman's disease. To further clarify the clinicopathological, immunohistochemical, and genotypical findings, we studied seven such patients. Clinically, these patients were characterized by localized disease and an indolent clinical course with a slowly growing bulky mass in the affected lymph node. Only one patient exhibited paraproteinemia. Histologically, the lesions were characterized by numerous evenly distributed germinal centers in extensive sheets of plasma cells. Various numbers of centrocyte-like (CCL) cells arranged in a marginal zone distribution pattern occupied the peripheral region of the lymph node. The majority of the lymphoid follicles had atrophic or regressive germinal centers. A few lymphoid follicles were colonized by CCL cells. Immunohistochemistry showed that all of the lesions contained a monoclonal plasma cell population. In three tumors, a number of the CCL cells had a similar light chain restriction pattern to that observed in plasma cells. Two of the four patients evaluated exhibited clonal bands for the IgH gene by polymerase chain reaction assay. Moreover, the presence of surface IgM+, IgD- and CD27+ CCL- cells suggests that these tumors are derived from memory B-lymphocytes.

Adult↗
PubMed2002

Primary cutaneous plasmacytoma: a clinicopathological study of two cases with a long-term follow-up and review of the literature.

BACKGROUND: Primary cutaneous plasmacytoma (PCP) is a rare type of cutaneous B-cell lymphoma arising primarily in the skin and derived from clonally expanded plasma cells with a various degrees of maturation and atypia. The disease is rare with only 30 cases reported so far. METHODS: Two cases of PCP with long-term follow-up of 17 and 15 years are presented. RESULTS AND CONCLUSIONS: Both patients were men with nodular lesions on the face. Histologically, the lesions were composed predominantly of variably maturated plasma cells with monotypic expression of immunoglobulin (Ig) lambda chains. Polymerase chain reaction for IgH genes did not reveal clonal rearrangement. Our cases are discussed in the context of previously reported cases of PCP with a long-term follow-up. We also include a review of all cases of PCP with known tumor progression earlier in the course of the disease (local relapse or visceral spread) to determine the clinical course of this primary cutaneous lymphoma.

Adult↗
PubMed1970

Studies of the rat immune response to plasmacytoma 5563 in C3H mice.

Washed lymphocytes from immunized rats showed no reaction against mouse plasmacytoma 5563 in vivo or in vitro.Cell-free lymph from immunized rats was shown to be cytotoxic to the tumour cells in vitro. This effect we have shown to be solely in the 19s fraction after Sephadex G-200 separation.This 19s fraction conferred partial protection to tumour bearing mice when given shortly after transplantation, but had negligible effect against late well established tumour.

Animals↗
PubMed1970

The growth characteristics of an ascitic plasmacytoma (MP 5563) terminating by fistulous communication with the blood-stream.

The growth of ascitic mouse plasmacytoma 5563 has been monitored by (51)Cr-RBC dilutions within the peritoneal cavity together with differential cell counts and protein measurements.Following the intraperitoneal transplantation of one million tumour cells, there is a latency period of 4 days, possibly explained as only a 5% survival of the inoculum. This is followed by logarithmic growth from 4 to 8 days with a doubling time of 18 hours, always similar in different animals. Eventually after 8 days and after about 100 million cells an asymptote is reached which is due to a fistula-like communication between blood-stream and peritoneal cavity. This terminal phase (9-10 days) is rapidly followed by death of the mouse.Reliable tumour cell counts can only be achieved between 4 and 8 days.

Animals↗
PubMed1976

Induction of resistance or enhancement to a transplantable murine plasmacytoma by transfer of non-immune leucocytes.

Newborn mice have a lower spontaneous resistance to the growth of a syngeneic plasmacytoma (MOPC-460) as compared to adult mice. The transfer of different leucocyte populations from non-immunized adult donors to newborn mice influence in a dual way the resistance to MOPC-460 growth, depending on the number of cells transferred. The transfer of a low number of neutrophils, thymus or spleen cells enhances the MOPC-460 takes. Higher numbers of neutrophils, thymus or bone marrow cells induce an effective protenction. By contrast, macrophages over a dose of 1 X 10(4) constantly produce a reduction of tumour growth.

Animals↗